Champions Oncology Q2 revenue $11.6M (-19% YoY); revises FY2024 guidance to flat

CHAMPIONS ONCOLOGY, INC.

2024-Q2 EPS reported -$0.34 revenue$24,134,000

Operating loss of $2.0M vs $7K income a year ago; adjusted EBITDA loss of $1.4M.
Gross margin fell to 42.8% from 47.9% on lower revenue and fixed costs.
FY2024 revenue guidance revised to be generally flat YoY, citing customer cancellations.
Hired Brady Davis as President to lead new strategic initiatives.
Corellia AI drug discovery advancing with two lead targets; seeking capital.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CHAMPIONS ONCOLOGY, INC. reported first six months of fiscal 2024 results: revenue $24.1 million.

Period: first six months of fiscal 2024
Revenue: $24.1 million
Result: reported results

Exact text from the filing

For the first six months of fiscal 2024, revenue decreased 13.9% to $24.1 million compared to $28.0 million for the first six months of fiscal 2023.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CHAMPIONS ONCOLOGY, INC. reported its second quarter of fiscal 2024, ended October 31, 2023 results: revenue $11.6 million. Guidance lowered.

Period: its second quarter of fiscal 2024, ended October 31, 2023
Revenue: $11.6 million
Guidance: lowered
Result: reported results

Exact text from the filing

Champions Oncology Reports Quarterly Revenue of $11.6 Million

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

CHAMPIONS ONCOLOGY, INC. filing history →

Source: SEC EDGAR

accession 0001628280-23-041308

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.